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A B S T R A C T
Schizophrenia (SCZ) is a severe psychotic disorder that affects up to 1% of the US population and it is associated with
progressive impairment in social functioning and cognition. Nonetheless, despite its high burden, the
pathophysiology of SCZ, including the genetic and biological mechanisms underlying the development and
manifestation of the disorder, remains largely elusive. Endophenotypes are subtypes of biological markers that are
more closely related to the genetic vulnerability for a disorder (e.g., SCZ). Recently, research on endophenotypes has
identified several parameters that may prove useful in shedding light over the underlying neurobiology of SCZ. In
this article, we provide an overview of the most established SCZ endophenotypes in the domains of neurocognition
(attention deficits, working and verbal declarative memory dysfunctions) and neurophysiology (pre-pulse
inhibition, anti-saccade impairment, event-related potential deficits) along with some novel, sleep-based measures
(reduced sleep spindles and sleep slow waves). We also discuss recent conceptual advances in the field that may lead
to novel, personalized treatment interventions for patients affected by this devastating mental illness.
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Introduction
Schizophrenia (SCZ) is a severe, major psychiatric disorder encompass-
ing a wide range of behavioral and cognitive dysfunctions. SCZ affects
approximately 1% of the US population [1] and ranks among the 15 leading
causes of disability worldwide [2]. Typically, a subthreshold prodromal
phase is followed by a first psychotic break - characterized by auditory
hallucinations, delusional thoughts, disorganized speech - occurring
during late adolescence or early adulthood. Afterwards, patients often
experience a chronic-relapsing clinical course that leads to progressive
impairment in social functioning and cognition [3].Despite the availability
of antipsychotic compounds that can effectively treat psychotic symptoms
[4], the need for prolonged, often lifetime pharmacological treatment,
associated with a wide variety of potential side effects, has a high impact on
patients’ lives and contributes to the substantial global burden of SCZ.
Furthermore, a treatment-resistant form of SCZ still accounts for about one
third of cases worldwide [5]. Persistent clinical and social impairments
observed in patients are largely due to an incomplete understanding of the
core pathophysiological mechanisms of the disorder. This has generated
considerableresearcheffort, bothat the basicandtranslational level, aimed
at characterizing the neurobiology of SCZ.
A leading approach to unveil the biological underpinnings of SCZ
involves the identification of genetic factors implicated in the risk and
development of the disorder [6]. In this context, genetic research initially
focused on twin studies to establish the heritability (h2) of SCZ. H2 is the
proportion of variance explained by genetic factors and provides a
measure of the genetic influence in certain characteristics (i.e., height) or
disorders (i.e., SCZ). The main findings of those twin studies included an
estimated heritability of 81 % for SCZ [7] and a concordance rate of 33 %
for SCZ in monozygotic twins [8]. These findings, however, provide no
direct information in terms of risk prediction at a single subject level.
Recent advances in genome sequencing methods have provided novel
insights onto heritability as well as on specific genes associated with SCZ.
Genome-wide association studies (GWAS) of common genetic variants
have suggested a heritability of 60–70 % for the SCZ spectrum [9]. These
studies considered differences in allele frequency of single nucleotide
polymorphisms (SNPs) and were able to initially identify specific genes
associated with susceptibility for developing SCZ, including those located
on chromosome 6p22.1, i.e. the region coding for the major histocom-
patibility complex (MHC) [10]. More recently, a multi-stage GWAS
analysis on more than 35,000 + SCZ cases and 110,000+ controls
reported 108 loci significantly associated with the disorder, 83 of which
had never previously been reported [11]. Those loci comprised genes that
are involved in glutamatergic transmission (such as DRD2) as well as
genes responsible for immune responses, including MHC-related loci.
Although promising, common SNPs identified with GWAS studies only
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reached statistical significance when comparing large SCZ and control
cohorts, raising concerns over their relevance at the individual subject
level. Indeed, most identified SNPs increase risk less than 1.1-fold above
general population risk [12]. Furthermore, the difference between
patient and control samples in the frequency of alleles associated with SCZ
risk is typically no more than 2%. Next-generation sequencing (NGS)
studies identify genetic variants, including copy number variants (CNVs),
that occur in only 1  2% of patients with SCZ diagnoses [13]. It has been
therefore challenging to find genetic features that are shared across large
groups of patients with this disorder.
To establish the influence of genetic factors on the pathophysiology of
SCZ, another research approach involves measuring so called “endophe-
notypes”, i.e. biological factors that are expressed along the path from the
genotype to the phenotype and are believed to be involved in the
pathological mechanisms of a disorder. Since the concept of endophe-
notype was introduced in psychiatric literature by Gottesman and Gould’s
seminal work [14], this line of research has rapidly developed.
Endophenotypes are a subtype of biological markers characterized by
the following specific criteria: 1) association with a disease; 2)
heritability; 3) ‘state-independence’, i.e. being present regardless of
illness phase; 4) co-segregation with the illness; 5) presence in unaffected
relatives of patients at a higher degree than in the general population.
These criteria aim to identify objective, quantifiable biological measures
associated with a clinical diagnosis (e.g., SCZ). As such, an ideal
endophenotype should point to a dysfunction in an identifiable brain
circuit associated with the genetic vulnerability for the disorder. It must
be pointed out, however, that the apparent association between an
endophenotype and the pathophysiology of a specific brain disorder may
result from endophenotype-related genes being in linkage equilibrium
with genes providing risk for the syndrome [15]. Furthermore, putative
endophenotypes may be indexing secondary or tertiary features that are
consequences of the primary pathophysiology. Altogether, these poten-
tial pitfalls may affect the validity of isolated endophenotypes as
pathophysiologically relevant markers of psychiatric disorders.
Several different candidate endophenotypes of SCZ have been
proposed [16,17], from cognitive sciences, to neurophysiology and
sleep research. In this article, we provide a brief overview of the most
established neurocognitive and neurophysiological SCZ endophenotypes
along with some novel, sleep-based measures. For each measure, we
highlight the putative specificity for SCZ (or lack thereof) by reporting,
when available, findings in other psychiatric syndromes. Particularly, we
will focus on overlaps between SCZ and affective psychoses, which has
been extensively studied under the Bipolar-Schizophrenia Network on
Intermediate Phenotypes (B-SNIP) initiative [18,19]. We also summarize
potential future directions for endophenotype research, which may shed
new light onto the pathophysiology of SCZ and related psychiatric
disorders, eventually leading to novel treatment interventions for
patients affected with this devastating mental illness.
Neurocognitive endophenotypes
SCZ is commonly associated with a progressive decline across multiple
neurocognitive domains. Cognition regulated by temporal and prefrontal
cortical areas is primarily affected, resulting in declarative and working
memory deficits, impaired verbal learning, and altered executive
functions [20–22]. These cognitive disturbances have a dramatic impact
on patients’ quality of life, leading to increased disability and poor
functional outcome [23,24]. Furthermore, increasing evidence indicates
that specific cognitive dysfunctions may represent putative endopheno-
types of SCZ. A multi-site initiative (Consortium on the Genetics of
Schizophrenia, COGOS) examined the genetic underpinnings of neuro-
cognitive biomarkers in families with high rates of SCZ, identifying
measures pertaining to attention, working memory and verbal declara-
tive memory as candidate endophenotypes [25]. Moreover, data from the
NAPLS consortium reported the predictive role of discrete neurocognitive
deficits in populations at clinical high risk for SCZ and related psychotic
disorders [26], confirming a role as putative endophenotypes for these
cognitive measures. In the following section, we present key findings
pertaining to the most established neurocognitive endophenotypes of
SCZ.
Attention deficits
Deficits in attention have been observed in SCZ since the first
descriptions of the disorder [27]. The inability of SCZ patients to sustain
focused attention has been studied extensively, thanks to the develop-
ment of reliable assessment tools, such as the Continuous Performance
Test (CPT) [28]. CPT-DS (degraded stimuli), which focuses on perceptual
attention, requires the identification of a blurred number or letter [29],
whereas CPT-IP (identical pairs), which is associated with higher working
memory load, involves the identification of the same stimulus in
consecutive trials (B. A [30].). In patients with SCZ, deficits in CPTs
appear to be trait-like (i.e., unrelated to the presence of clinical
symptoms) [31] and are unaffected by medication status [32].
Consistently with the endophenotype criteria, attention deficits are also
reported in offspring of SCZ probands, including in children who would
eventually develop a disorder within the SCZ spectrum [33]. It is worth
noting, however, that attention deficits are a common feature among
several psychiatric populations, including euthymic bipolar patients
[34].
Working memory (WM) dysfunction
WM refers to the ability to retain short-term, goal-oriented
information needed for the execution of a specific task [35]. Methods
used to quantify WM deficits include the Letter-Number Sequencing
(LNS) task from the Wechsler Memory Scale III [36]. The LNS task
involves showing to a participant a series of letters and numbers (2–8
total), which should be repeated in the order they were presented
(forward condition), or in ascending/alphabetical order (reorder
condition). SCZ patients, regardless of their clinical state, perform
significantly worse than healthy controls in LNS tasks [37]. Unaffected
first-degree relatives (FDRs) tend to perform better than SCZ
probands, but significantly worse than the healthy population [38].
Thus, a role for WM deficits as SCZ endophenotype appears plausible
[39,40]. Notably, genetic studies have shown that polymorphisms of
catechol-o-methyl transferase (COMT) genes and D1 dopamine
receptors [41], both of which have been implicated in SCZ, are
involved in regulating WM function, thus strengthening the theoreti-
cal framework linking WM deficits to the neurobiology of SCZ. While
spatial WM deficits appear fairly specific for SCZ, this is not the case
for performances in numeric tasks, that appear equally affected in
Bipolar Disorder [42].
Verbal declarative memory (VDM) deficits
VDM refers to a subtype of long-term memory that reflects the
ability to recollect events occurred to the subject (episodic memory), or
facts learnt by the subject (semantic memory). Dysfunctions of VDM are
associated with encoding deficits, higher rates of forgetting, and
inability to recall words. VDM impairments have been found in patients
with SCZ [43] and appear to be largely independent from medication
status, duration of illness, and positive symptoms, although a
significative association with negative symptoms has been reported
[44]. VDM deficits are also present, to a lesser degree, in unaffected
FDRs of SCZ probands as well as in subjects at high risk for developing
psychosis [45], thus suggesting an association between VDM dysfunc-
tions and the genetic risk of developing SCZ. However, VDM is known
to be reduced in a number of psychiatric syndromes, including affective
disorders [46].
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Neurophysiological endophenotypes
Neurophysiological parameters closely reflect the activity of under-
lying neuronal circuits, thus representing ideal biomarkers for psychiatric
disorders. Here, we will provide an overview of neurophysiological
measures most consistently found to be altered in SCZ, which have also
shown to be linked to the genetic risk for this disorder (i.e.,
neurophysiological endophenotypes). Specifically, we will first present
well-established neurophysiological endophenotypes measured during
wakefulness, which comprise Pre-Pulse Inhibition, Oculomotor anti-
saccades, Mismatch negativity, and P300. We will then discuss novel
candidate endophenotypes recently observed during sleep in SCZ, which
including sleep slow waves and sleep spindles. Furthermore, we will
highlight known overlaps between SCZ and other psychiatric disorders,
including affective psychoses (for a review on this latter topic see [47]).
Pre-Pulse Inhibition (PPI) deficits
PPI is defined as the physiological dampening of a startle response to a
loudtone,whensuchtoneisprecededbyaless intenseauditorystimulus(i.e.,
the ‘pre-pulse’) [48]. Inanimalstudies,PPIhasbeenfound tooriginatefroma
small cluster of neurons in the nucleus reticularis pontis caudalis of the
reticular formation [49]. The startle response, assessed with electromyo-
graphic recording of the orbicularis oculi muscle, is significantly less
attenuated by exposure to a pre-pulse in patients affected by SCZ relative to
healthy controls [50–52]. In those patients, PPI deficits tend to be stable over
time and are unrelated to their clinical state [53]. Furthermore, PPI deficits
were found in unaffected FDRs of SCZ probands, suggesting a link between
PPI deficits and the genetic loading for SCZ [54–56]. Atypical antipsychotic
medicationscanamelioratePPIdeficits,asestablishedbothinanimalmodels
and in SCZ patients [57,58]. However, PPI impairments are not exclusively
found in the SCZ spectrum, having been reported in obsessive-compulsive
disorder, attention deficit disorder, and Huntington's disease [51]. PPI was
recently investigatedinalargegroupofpatientsaffectedbySCZandaffective
psychoses under the B-SNIP initiative, where it showed no significant
differences between each set of probands and healthy controls [59].
Oculomotor anti-saccade (AS) impairment
The term ‘saccade’ defines a quick, simultaneous movement of both eyes
from one point of fixation towards another one, so that the image of a
previouslyperipheral targetmay be capturedby the fovea. ASrepresents the
ability to suppress a saccade towards a visual stimulus, and voluntarily
direct the gaze towards the opposite direction. During AS tasks, subjects are
asked to fixate a central target and, whenever a flashing stimulus appears on
one side of the screen, they are prompted to look to the opposite side.
Physiological mechanism underlying AS are complex and appear to depend
on competitive stimulus selection in the superior colliculus [60]. Patients
suffering from SCZ show longer latencies to correct eye movements in AS
tasks, when compared to HC [61], which likely reflects a lack of inhibitor
control [62]. Studies in unaffected FDR of SCZ probands have reported an
intermediate degree of AS deficits in those individuals [63]. However, AS
tasks require participants’ active engagement, attention and motivation.
Therefore, deficits in cognitive domains, including attention and visuo-
motor coordination, may affect the reliability of AS measures, especially in
acutely ill patients [64]. Furthermore, AS deficits were reported in other
psychiatric disorders and particularly in affective syndromes [65,66].
Recently, a B-SNIP study in a large sample of patients showed that AS
impairment are present acrossaffective and non-affective psychoses and are
associated with a non-coding region on chromosome 7 [67].
Mismatch negativity (MMN) deficits
Event related EEG potentials (ERPs), such as MMN and P300, have
played a major role in psychiatry research, particularly in SCZ. MMN
refers to the negative shift in scalp EEG potential recorded 50200 ms
after the presentation of a deviant stimulus embedded in a series of
repetitive stimuli (i.e., oddball task). MMN is independent from attention
and is thought to reflect automatic memory processing at lower level of
awareness [68]. While the neural mechanisms underlying MMN still need
to be fully elucidated, recent evidence suggests a contribution of lateral
inhibition [69]. Deficits in MMN have been consistently reported in
patients with SCZ [70,71] and appear to be relatively specific for this
disorder [72]. MMN responses are reduced in unaffected relatives of SCZ
patients [73] and in at-risk individuals, where they appear to have a role
in predicting transition to full-blown psychosis and SCZ [74,75].
Interestingly, MMN abnormalities appear to be relatively specific for
SCZ, being absent in patients with affective disorders (Umbricht 2003 Biol
Psych) and obsessive-compulsive disorder [76]. Furthermore, MMN
deficits is associated with poor functioning and disability in SCZ patients
[77] and was recently found to discriminate remitters versus non-
remitters [78], thus indicating a putative prognostic value and related
potential clinical applications.
P300 deficits
The P300 is a positive evoked EEG potential recorded about 300 ms
after a deviant, infrequent stimulus is presented in an oddball task, while
the subject focuses attention on detecting these infrequent stimuli (e.g. if
asked to keep count of them). More complex paradigms include a 3-
stimuli setting – a frequent stimulus, a deviant non-target stimulus, and a
deviant target stimulus – where deviant stimuli elicit so called P3a and
P3b responses, respectively. P3a is believed to originate from stimulus-
driven frontal attentional mechanisms, while P3b is thought to be related
to temporoparietal activity associated with attention [79]. Deficits in
P300 have been extensively studied in SCZ, and both a reduced amplitude
and an increased latency of the P300 have been consistently reported
[80]. Furthermore, the same P300 parameters are also abnormal in FDRs
of SCZ patients, when compared to healthy controls [81]. In a recent study
by the NAPLS consortium, P300 for deviant auditory target stimuli
predicted transition to psychosis in at-risk individuals, as opposed to P300
for deviant non-target stimuli [82]. It should however be pointed out that
altered P300 is not a finding limited to the SCZ spectrum, having also been
reported in patients with Bipolar Disorder and their unaffected FDRs [83].
Data from the B-SNIP study suggest that P3b amplitude deficits may be
specific to schizophrenia, while reduced P3a amplitude may be a shared
feature across psychotic disorders [84]. Interestingly, a recent study
reported that P300 amplitude and P300 latency were not related with
each other, thus suggesting different biological factors underlying
abnormalities in this same domain of information processing [85].
Sleep endophenotypes: Sleep slow waves and sleep spindle impairment
In clinical settings, sleep disturbances are commonly observed in SCZ
patients [86], including early course patients and individuals at clinical
high risk for psychosis [87]. These observations have generated great
interest in assessing the implication of sleep in the pathophysiology of SCZ
and related disorders. While initial research was primarily directed
towards investigating abnormalities in sleep architecture (i.e., the basic
structural organization of sleep), with inconsistent findings (for a review,
see [88]), more recent work has focused on sleep-specific EEG rhythms,
including slow wave and sleep spindles. Slow waves are 0.81 Hz, large
amplitude oscillations which dominate the deepest stage of non-rapid eye
movement sleep (NREM N3) and are primarily generated and coordinated
within the cortex [89]. Sleep spindles are 1216 Hz, waxing and waning
oscillations that characterize NREM N2 sleep. Spindles are initiated
within the thalamus and are regulated by thalamo-cortical circuits,
specifically by the synchronous firing of GABA-ergic, parvalbumin
positive interneurons located in the thalamic reticular nucleus [90].
Spindle and, to lesser extent, slow wave abnormalities have been
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established by several sleep EEG studies in patients of SCZ, including
medication-naïve and first-episode psychosis individuals, and alterations
in spindle and slow wave have been also recently reported in FDRs of SCZ
probands, as detailed below.
A decrease in slow wave power [91] and other slow wave parameters
[92] has been reported in SCZ patients during sleep, although other sleep
studies found no difference between SCZ and control samples [93–96]. In-
depth reviews of these findings are available elsewhere [97,98].
Furthermore, our group recently found that reduced slow wave density
was present in first-episode psychosis patient and correlated with the
severity of their positive symptoms [99]. We have also established that
FDRs of SCZ probands had decreased slow wave amplitude and slopes,
when compared to age and gender matched individuals with no family
history of SCZ [100]. While future studies are needed to replicate these
findings in large groups of FDRs and to further explore their genetic
underpinning, this work indicates that slow wave abnormalities may
represent a putative endophenotype for SCZ.
Sleep spindle power and several other spindle parameters, including
amplitude, duration, density, and integrated spindle activity (ISA), were
found to be reduced in chronic SCZ patients relatively to HC [101]. Sleep
spindle deficits were unaffected by antipsychotic medications [93] and
were also reported in early course SCZ [102] and first-episode psychosis
patients ([99] [103],). Furthermore, recent work from our and other
research groups reported impaired spindle parameters in healthy FDRs of
patients affected by SCZ relative to individuals with no family history of
SCZ [100,102,104], consistent with a candidate endophenotype of SCZ.
However, one study has questioned the specificity of sleep spindles
deficits for SCZ, showing reduced fast spindles density and frequency in a
cohort of patients affected by Bipolar Disorder in euthymic phase [105].
Spindle parameters have also been correlated with cognitive
measures, such as intellectual ability (e.g. IQ) [106] in the general
population, and are thought to mediate procedural and declarative
memory consolidation and learning in animal models and in humans
[107–110]. Furthermore, reduced sleep spindles were associated with
diminished overnight learning in SCZ [96] and with impaired cognitive
abilities in psychotic disorders and unaffected FDRs of SCZ patients
[102]. Altogether, these findings suggest that spindles deficits are related
to the cognitive impairment of SCZ patients and their FDRs. Thanks to
advances on the genetic bases of sleep spindle activity [111], the
theoretical framework linking risk SCZ genes (i.e. CACNA1I, a Ca +
channel that regulate the spindle oscillation) to specific neural
dysfunctions (i.e. reduced sleep spindles) and clinically relevant
behavioral features (i.e. cognitive impairment) is testable and will
inform future studies investigating sleep spindles as a treatable
neurophysiological endophenotype linking genetic risk to impaired
cognition in SCZ [112].
Conclusions
Heterogeneity in clinical presentation inherently affects both
nosology and research of major psychiatric disorders, including SCZ.
Current classification systems [113,114], which are based on behavior
rather than neurobiology, indeed provide a partially validated
framework that mental health professionals can use to deliver
reproducible diagnoses and share research results. Nevertheless, the
implicit imprecision of such classification systems can affect research-
ers’ ability to gain a deeper understanding on the neurobiology
underlying behavioral phenotypes [115]. The aim to fill this gap and
“deconstruct” SCZ and other major psychiatric disorders into biologi-
cally validated constructs – genetically informed and testable in
translational animal models – has generated extensive efforts to
identify reliable endophenotypes. Here, we provided an overview of the
most established candidate endophenotypes for SCZ in the domains of
neurocognition and neurophysiology. We also presented emerging
sleep-based putative electrophysiological endophenotypes of SCZ that
have recently been proposed by our and other research groups. In this
last section, we will briefly discuss how the growing knowledge on
endophenotypes may springboard future studies to progress our current
understanding of the pathophysiology of SCZ. How this might reveal
shared abnormalities across major psychiatric disorders, which may
then set the stage for tangible advances in treatment, will also be
addressed.
Although potentially relevant in shedding light on the pathophysio-
logical mechanisms of psychotic disorders, the co-occurrence of
endophenotypes within and across these disorders remains largely
uninvestigated. The majority of research studies investigating this issue
has focused on the co-occurrences of different cognitive measures [116–
118]. A recent study investigated the associations between P300,
ventricular volumes on brain imaging, and several cognitive measures
in a large cohort of patients affected by psychotic disorders (including
SCZ) and in unaffected FDRs [85]. P300 amplitude was related to
measures of working memory but not to VDM. Nevertheless, more
research is needed in order to clarify the co-occurrence of endopheno-
types in psychotic disorders, including sleep endophenotypes, and
identify common pathways to help narrowing the biological heterogene-
ity of psychotic disorders.
Future work should employ existing and novel endophenotypes to
enrich genetic studies of SCZ. This may provide insights on the overlap in
genetic vulnerability between SCZ and a specific endophenotype [17].
For example, a recent GWAS study that aimed to elucidate genetic
correlates of AS deficits in psychotic disorders identified several genetic
variants associated with both psychosis and AS deficits [67]. A similar
approach could be employed to explore the relationship between genetic
variants associated with increased risk for SCZ (e.g. CACNA1I, which
regulate Ca + Channels expression in neurons of the reticular thalamic
nucleus, the sleep spindle pacemaker) and the sleep endophenotype (e.g.
reduced sleep spindles) in SCZ probands and FDRs.
Another future application involves combining several endopheno-
types to characterize genetic risk for SCZ and related psychiatric
disorders. In this regard, in a recent, elegant study Clementz et al.
identified three neurobiologically distinct ‘biotypes’ of psychosis by
characterizing a number of endophenotypes (neurocognitive, imaging-
based, EEG-based) in subjects diagnosed with SCZ and other types of
psychosis, including Schizoaffective Disorder and Bipolar Disorder with
psychotic symptoms [119]. Biotype 1 showed weaker responses to
sensory stimuli; Biotype 2 had higher neural activity during auditory
stimulation tasks; Biotype 3 appeared closer to healthy subjects in most
tasks results. Interestingly, these biotypes did not overlap with diagnoses
based on current classification systems. Moreover, authors recently
showed that frequency patterns of intrinsic activity (IA, or “ongoing high-
frequency”, i.e. the neural activity recorded between evoked stimuli,
could successfully discriminate Biotype 1 (low IA) and Biotype 2 (high
IA), and that IA correlated with the level of active psychotic symptoms,
again regardless of DSM-5 diagnosis [120]. By applying a similar
approach to unaffected FDRs, future studies could reveal how genetic risk
translates into neurobiological and neurocognitive abnormalities that
may require targeted interventions in patients.
The observation that some endophenotypes are shared across psychosis
spectrum disorders is consistent with the idea that these measures may
promote conceptual advances in psychiatric nosology. Specifically, future
research on endophenotypes in psychiatry should encourage a shift from
phenomenological diagnosis-based paradigms to neurobiology-driven
subtyping of psychiatric populations. Endophenotypes should therefore
be investigated not just as correlates of specific clinical diagnosis, but
primarily as neural traces associated with distinct, transdiagnostic
dimensions of psychopathology (e.g. anhedonia, irritability, anxiety), as
recently proposed by Beauchaine et al. [121]. In this perspective,
endophenotypes would represent markers of genetic vulnerability to basic
behavioral traits that, when interacting, give rise to complex clinical
patterns, as reflected by the heterogeneity of current diagnostic categories.
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Along these lines, recent data from the B-SNIP study showed a degree
of overlapping of clinical, neurocognitive, neurophysiological and
imaging derived measures across affective and non-affective psychoses
[67,122–124]. In accordance with such evidence, Keshavan et al. recently
proposed a valuable four-step approach aiming to deconstruct clinically
diagnosed syndromes and redefine psychiatric nosology with a “bottom-
up”, biomarkers informed, disease definition [125]. This approach, while
pointing towards a dimensional reconceptualization of psychiatric
diagnostics, may also inform the clinical routine performed within the
current diagnostic framework. For example, biomarkers and endophe-
notypes may help identify subtypes of clinically diagnosed syndromes
(e.g. subtypes of SCZ) based on biological features. Consistent with this
assumption, Chand et al. [126] recently reported two distinct forms of
SCZ identified by machine learning techniques applied to brain imaging
data. These two biologically informed “clinical subtypes” of SCZ may then
be targeted by more effective pharmacological and non-pharmacological
interventions in the clinical practice. Altogether, advances in our current
theoretical framework on the role of endophenotypes in psychiatry are
well in line with the Research Domain Criteria Initiative [127] and may
have significant impact in clinical settings in the foreseeable future.
Indeed, the use of endophenotypes to identify subgroups of patients
across and within psychiatric diagnoses (e.g. Biotypes of psychosis in SCZ)
may lead to new advances in precision medicine in psychiatry. The shift
towards brain circuitry from diagnostic criteria may pave the way for the
development of targeted therapies to address specific neurobiological
vulnerabilities. This will be particularly relevant for patients impaired by
symptom domains that are resistant to currently available treatments,
such as cognition in SCZ.
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